[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Jianfeng Xie\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":69},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100632793","phase-4-nafamostat-mesylate-versus-regional-citrate-anticoagulation-for-continuous-renal-replacement-therapy-in-sepsis-associated-acute-kidney-injury-100632793",false,"NCT07518303","Nafamostat Mesylate Versus Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy in Sepsis-Associated Acute Kidney Injury","NICE-AKI","Inclusion Criteria:\n\n* Age 18 to 90 years, inclusive, regardless of sex.\n* Meets Sepsis 3.0 diagnostic criteria and develops acute kidney injury within 7 days after the diagnosis of sepsis.\n* After adequate resuscitation, meets KDIGO 2012 stage 2 or stage 3 acute kidney injury criteria, including any of the following:\n\nSerum creatinine increased to more than 3 times baseline; or Serum creatinine ≥4.0 mg\u002FdL \\[353.6 μmol\u002FL\\]; or Urine output \\\u003C0.3 mL\u002Fkg\u002Fh for ≥24 hours; or Anuria, defined as extremely low or absent urine output, lasting ≥12 hours.\n\nOr has an indication for CRRT, including any of the following:\n\nBlood urea nitrogen \\>150 mg\u002FdL; or Serum potassium \\>6 mmol\u002FL; or pH \\\u003C7.15; or Organ edema and\u002For fluid overload in the setting of AKI that is refractory to diuretic therapy.\n\n* Expected duration of CRRT treatment \\>48 hours.\n* Written informed consent obtained.\n\nExclusion Criteria:\n\n* Requirement for therapeutic anticoagulation, such as pulmonary embolism or deep vein thrombosis.\n* Contraindication to systemic anticoagulation.\n* Hemolytic uremic syndrome or thrombotic thrombocytopenic purpura.\n* Acute liver failure and\u002For shock with persistent severe lactic acidosis, defined as two consecutive measurements of pH \\\u003C7.2 lasting for more than 2 hours, with lactate \\>72.1 mg\u002FdL \\[8 mmol\u002FL\\].\n* Chronic kidney disease requiring long-term regular dialysis.\n* Acute kidney injury caused by permanent bilateral renal artery occlusion or surgical injury.\n* Acute kidney injury caused by glomerulonephritis, interstitial nephritis, or vasculitis.\n* Known allergy to study drugs, including nafamostat mesylate, sodium citrate, or their excipients.\n* Kidney transplantation within 1 year.\n* Planning pregnancy in the near term, pregnancy, or lactation.\n* HIV infection.\n* Only adsorptive filters such as oXiris are available at study enrollment.\n* Participation in another clinical trial within the previous 3 months.\n* Judged by the investigator to be in a moribund state or unlikely to complete the study intervention and primary outcome assessment, including but not limited to expected death within 24 hours after enrollment, decision for do-not-resuscitate order or limitation\u002Fwithdrawal of life-sustaining treatment, or planned abandonment of active treatment and self-discharge within 24 hours due to terminal disease or patient\u002Ffamily preference.\n* Any other condition that, in the investigator's judgment, makes the patient unsuitable for enrollment.","ALL","18 Years","90 Years",{"count":20,"type":21},1162,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This multicenter, randomized, open-label, active-controlled, parallel-group trial will evaluate the efficacy and safety of nafamostat mesylate anticoagulation compared with regional citrate anticoagulation in adult patients with sepsis-associated acute kidney injury requiring continuous renal replacement therapy. Eligible participants will be randomized in a 1:1 ratio to receive either nafamostat mesylate or regional citrate anticoagulation during CRRT. The primary outcome is MAKE30, a composite of all-cause mortality, new or ongoing renal replacement therapy, or persistent renal dysfunction within 30 days after randomization. Secondary outcomes include filter lifespan, CRRT-free days, 30-day all-cause mortality, renal replacement therapy status, persistent renal dysfunction, ICU and hospital mortality, length of stay, CRRT duration, major bleeding, new bloodstream infection during ICU stay, SOFA score, number of filters used, and protocol-defined safety outcomes.",[27,28,29],"Sepsis","Acute Kidney Injury","Continuous Renal Replacement Therapy (CRRT)",[31,29,27,32,33],"Nafamostat Mesylate","Acute Kidney Injury (AKI)","Randomized Clinical Trial (RCT)","NOT_YET_RECRUITING","2026-06-01",{"date":37,"type":38},"2026-06-03","ACTUAL",{"date":40,"type":21},"2026-06-10",{"date":42,"type":21},"2028-12-10",{"name":44,"class":45},"Jianfeng Xie","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100612555","epidemiological-investigation-of-central-venous-catheter-related-bloodstream-infections-in-icus-in-china-100612555","NCT07255105","Epidemiological Investigation of Central Venous Catheter-related Bloodstream Infections in Icus in China","The First Phase of the Closed-loop Improvement Project for Preventing CLABSI","Inclusion Criteria:\n\n* 1\\. Admitted to the ICU with a central venous catheter placed in place and the expected indwelling time exceeds 48 hours (including newly placed central venous catheters or the continued indwelling of existing qualified central venous catheters)\n\n  2\\. Patients aged 18 or above\n\n  3\\. Sign the informed consent form\n\nExclusion Criteria:\n\n1. Patients who have had a central venous catheter indwelled for more than 24 hours before being admitted to the ICU (and are not going to have it replaced immediately)\n2. Patients who were re-admitted to the ICU during the study period\n3. Lactating and pregnant women",{"count":54,"type":21},1846,"OBSERVATIONAL","In recent years, with the rapid advancement of medical technology and the rapid development of critical care medicine, the use of various central venous catheters in icus has been increasing day by day. Central venous catheter-related bloodstream infection (CLABSI), as a common catheter complication, preventable nosocomial acquired infections have gradually become a focus of attention in the ICU. Once CLABSI occurs, it often leads to a mortality rate as high as 28% to 30% for patients. Data from our country shows that patients with CLASBI will have their hospital stay extended by 8 to 13 days. The additional cost has increased by 3,500 US dollars.\n\nTherefore, over the years, medical systems both at home and abroad have been committed to the prevention and control of CLABSI. The incidence of CLABSI in icus in the United States in 2020 was 0.87 per thousand catheter days. In 2018, the incidence rate of CLABSI in 79 icus in China was 1.5 per thousand catheter days. All the above incidence rates have decreased significantly compared with previous data.\n\nDuring the COVID-19 pandemic in 2020, the global healthcare system faced severe challenges. Particularly, factors such as the aggravation of patients' conditions in icus, the sharp increase in the use of central venous catheters, the shortage of medical staff, and the ineffective implementation of CLABSI prevention measures jointly led to a significant increase in the incidence of CLABSI. The number of CLABSI cases recorded by the US NHSN in the fourth quarter increased by as much as 47%. In response to this crisis, international and domestic authoritative institutions responded promptly: In 2022, the American Society of Epidemiology (SHEA) updated its prevention strategy for CLABSI. In the same year, the National Health Commission of China emphasized in its medical quality improvement goals the need to reduce intravascular catheter-related infections, especially in the field of critical care medicine, and explicitly indicated the need to lower the incidence of CLABSI in icus.\n\nHowever, at present, there is still no large-scale investigation on the incidence of CLABSI after COVID-19 in Chinese mainland. This is related to the fact that there is no standard data collection and monitoring platform at present, and the judgment standards and capabilities of various medical institutions are inconsistent.\n\nThis study took adult patients with central venous catheters in icus across the country as the research subjects. Through a prospective cohort study, the current incidence and related influencing factors of CLABSI were clarified. To provide a basis and reference for further formulating and implementing CLBASI prevention strategies in the future.",[58],"CLABSI - Central Line Associated Bloodstream Infection","RECRUITING","2025-11-19",{"date":62,"type":38},"2025-11-28",{"date":64,"type":38},"2025-06-08",{"date":66,"type":21},"2026-09-30",{"name":44,"class":45},1,""]